Abstract

Oseltamivir is a neuraminidase inhibitor that inhibits influenza virus proliferation, and is used as an antiviral drug against influenza A and B viruses. Recently, concerns have been raised about hallucinations, delirium, and abnormal activity after administration of oseltamivir for treatment of infection with influenza virus. A large epidemiologic study was conducted in Japan in the winter of 2006-2007 to assess the relationship between oseltamivir intake and adverse behaviors, and an interim report was released on 10 July 2008. In the report, the research group concluded that no positive associations were detected between oseltamivir intake and abnormal behaviors. However, the analytic method used in the study was flawed. A correct analysis (based on person-time) shows a rate ratio of 1.57 (95% confidence interval = 1.34-1.83). This example clearly illustrates the importance of persontime in the analysis of cohort studies.

Original languageEnglish
Pages (from-to)619-621
Number of pages3
JournalEpidemiology
Volume20
Issue number4
DOIs
Publication statusPublished - Jul 2009

Fingerprint

Oseltamivir
Orthomyxoviridae
Influenza B virus
Delirium
Hallucinations
Influenza A virus
Neuraminidase
Antiviral Agents
Epidemiologic Studies
Japan
Cohort Studies
Confidence Intervals
Infection
Research

ASJC Scopus subject areas

  • Epidemiology

Cite this

Oseltamivir and abnormal behaviors. / Yorifuji, Takashi; Suzuki, Etsuji; Tsuda, Toshihide.

In: Epidemiology, Vol. 20, No. 4, 07.2009, p. 619-621.

Research output: Contribution to journalArticle

@article{bcc8cfbc601e48f09aa2e207958de391,
title = "Oseltamivir and abnormal behaviors",
abstract = "Oseltamivir is a neuraminidase inhibitor that inhibits influenza virus proliferation, and is used as an antiviral drug against influenza A and B viruses. Recently, concerns have been raised about hallucinations, delirium, and abnormal activity after administration of oseltamivir for treatment of infection with influenza virus. A large epidemiologic study was conducted in Japan in the winter of 2006-2007 to assess the relationship between oseltamivir intake and adverse behaviors, and an interim report was released on 10 July 2008. In the report, the research group concluded that no positive associations were detected between oseltamivir intake and abnormal behaviors. However, the analytic method used in the study was flawed. A correct analysis (based on person-time) shows a rate ratio of 1.57 (95{\%} confidence interval = 1.34-1.83). This example clearly illustrates the importance of persontime in the analysis of cohort studies.",
author = "Takashi Yorifuji and Etsuji Suzuki and Toshihide Tsuda",
year = "2009",
month = "7",
doi = "10.1097/EDE.0b013e3181a3d3f6",
language = "English",
volume = "20",
pages = "619--621",
journal = "Epidemiology",
issn = "1044-3983",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Oseltamivir and abnormal behaviors

AU - Yorifuji, Takashi

AU - Suzuki, Etsuji

AU - Tsuda, Toshihide

PY - 2009/7

Y1 - 2009/7

N2 - Oseltamivir is a neuraminidase inhibitor that inhibits influenza virus proliferation, and is used as an antiviral drug against influenza A and B viruses. Recently, concerns have been raised about hallucinations, delirium, and abnormal activity after administration of oseltamivir for treatment of infection with influenza virus. A large epidemiologic study was conducted in Japan in the winter of 2006-2007 to assess the relationship between oseltamivir intake and adverse behaviors, and an interim report was released on 10 July 2008. In the report, the research group concluded that no positive associations were detected between oseltamivir intake and abnormal behaviors. However, the analytic method used in the study was flawed. A correct analysis (based on person-time) shows a rate ratio of 1.57 (95% confidence interval = 1.34-1.83). This example clearly illustrates the importance of persontime in the analysis of cohort studies.

AB - Oseltamivir is a neuraminidase inhibitor that inhibits influenza virus proliferation, and is used as an antiviral drug against influenza A and B viruses. Recently, concerns have been raised about hallucinations, delirium, and abnormal activity after administration of oseltamivir for treatment of infection with influenza virus. A large epidemiologic study was conducted in Japan in the winter of 2006-2007 to assess the relationship between oseltamivir intake and adverse behaviors, and an interim report was released on 10 July 2008. In the report, the research group concluded that no positive associations were detected between oseltamivir intake and abnormal behaviors. However, the analytic method used in the study was flawed. A correct analysis (based on person-time) shows a rate ratio of 1.57 (95% confidence interval = 1.34-1.83). This example clearly illustrates the importance of persontime in the analysis of cohort studies.

UR - http://www.scopus.com/inward/record.url?scp=67651017973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651017973&partnerID=8YFLogxK

U2 - 10.1097/EDE.0b013e3181a3d3f6

DO - 10.1097/EDE.0b013e3181a3d3f6

M3 - Article

VL - 20

SP - 619

EP - 621

JO - Epidemiology

JF - Epidemiology

SN - 1044-3983

IS - 4

ER -